These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 8821405)
1. New aspects in the histological diagnosis of breast carcinoma. Shousha S Semin Surg Oncol; 1996; 12(1):12-25. PubMed ID: 8821405 [TBL] [Abstract][Full Text] [Related]
2. Pathology of the breast. Litzky LA Semin Roentgenol; 1993 Jul; 28(3):259-67. PubMed ID: 8211234 [No Abstract] [Full Text] [Related]
3. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer]. Wang YJ; Wang N; Wang B; Qin WX; Xue CY Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082 [TBL] [Abstract][Full Text] [Related]
4. Synchronous squamous cell carcinoma of the breast and invasive lobular carcinoma. Sentani K; Tashiro T; Oue N; Yasui W APMIS; 2007 Dec; 115(12):1422-5. PubMed ID: 18184414 [No Abstract] [Full Text] [Related]
5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
6. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403 [TBL] [Abstract][Full Text] [Related]
7. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090 [TBL] [Abstract][Full Text] [Related]
8. Topographical, morphological and immunohistochemical characteristics of carcinoma in situ of the breast involving sclerosing adenosis. Two distinct topographical patterns and histological types of carcinoma in situ. Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Shiraiwa M; Nishida C; Morita T; Sato Y; Hayashi T; Kato A; Aoyama H; Yoshikawa K Histopathology; 2011 May; 58(6):835-46. PubMed ID: 21401704 [TBL] [Abstract][Full Text] [Related]
9. Nucleolar organizer regions in human breast cancer. Roller E; Fritz P; Wicherek C; Klumpp B; Lauinger J; Mischlinski A; Wanner B; Schumacher K Zentralbl Pathol; 1993 Aug; 139(3):195-9. PubMed ID: 8218120 [TBL] [Abstract][Full Text] [Related]
10. Fine-needle aspiration of the breast: diagnostic problems and approaches to surgical management. Sneige N; Singletary SE Pathol Annu; 1994; 29 Pt 1():281-301. PubMed ID: 8127626 [No Abstract] [Full Text] [Related]
11. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
12. Multinucleated stromal giant cells in breast lesions. Ryska A Acta Cytol; 2003; 47(1):112-3. PubMed ID: 12585045 [No Abstract] [Full Text] [Related]
13. [Stereotactic breast biopsy: comparison of vacuum punch biopsy versus high speed core biopsy]. Sedivy R; Partik B; Helbich T; Breitenecker G; Wolf G Wien Med Wochenschr; 1998; 148(14):331-4. PubMed ID: 9816644 [TBL] [Abstract][Full Text] [Related]
14. Benign proliferative lesions and in situ carcinoma of the breast: new immunohistological findings and their biological implications. Böcker W; Bier B; Ludwig A; de Hesselle B; Gerdes J Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():41-9. PubMed ID: 7507748 [No Abstract] [Full Text] [Related]
15. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Park SS; Kim SW Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359 [TBL] [Abstract][Full Text] [Related]
16. Carcinoma in a fibroadenoma. Sarela AI; Madvanur AA; Soonawala ZF; Shah HK; Pandit AA; Samsi AB J Postgrad Med; 1995; 41(1):19-20. PubMed ID: 10740697 [TBL] [Abstract][Full Text] [Related]
17. Role of E-cadherins in development of lymphatic tumor emboli. Gupta A; Deshpande CG; Badve S Cancer; 2003 May; 97(9):2341-7. PubMed ID: 12712492 [TBL] [Abstract][Full Text] [Related]
18. Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders. Sasano H; Frost AR; Saitoh R; Matsunaga G; Nagura H; Krozowski ZS; Silverberg SG Anticancer Res; 1997; 17(3C):2001-7. PubMed ID: 9216657 [TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer]. Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186 [TBL] [Abstract][Full Text] [Related]
20. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]